Chronic knee pain from osteoarthritis affects a large share of older adults, and not everyone wants — or is a candidate for — knee replacement surgery. Genicular artery embolization has emerged as an interventional radiology option for some patients with knee osteoarthritis pain who have not achieved adequate relief from conservative measures. As a newer application of embolization technology, it is worth understanding both how it is thought to work and what the current evidence base does and does not establish.
What Is Genicular Artery Embolization?
Genicular artery embolization (GAE) is a catheter-based procedure in which small blood vessels called genicular arteries, which supply the tissue surrounding the knee joint, are selectively targeted with embolic material. The genicular arteries are accessed through the arterial system, commonly via the groin, using imaging guidance to navigate to the small branches around the knee. Embolic agents are then delivered to reduce abnormal blood flow associated with synovial inflammation in the osteoarthritic joint.
What Is the Proposed Mechanism Behind Pain Relief?
The rationale behind GAE is linked to observations that osteoarthritic joints commonly develop increased and abnormal blood vessel growth (neovascularization) within the synovium, the tissue lining the joint. This abnormal vascularity is thought to be associated with chronic low-grade inflammation and pain signaling in the joint. By reducing blood flow to these abnormal vessels through embolization, the procedure is intended to reduce the inflammatory drivers of pain — though the joint's underlying structural degeneration from osteoarthritis is not reversed by this approach.
What Does the Current Evidence Show?
Interventional radiology literature on genicular artery embolization has grown over recent years, with published studies reporting improvement in pain scores and function for many treated patients in the months following the procedure. As with any relatively newer application of an established technology, published follow-up periods vary between studies, and the durability of benefit over multi-year timeframes continues to be an area of ongoing research. Patients considering GAE should ask their treating physician about the specific evidence relevant to their situation, since study populations and outcome measures differ across published reports.
Who Is Typically Considered for This Procedure?
GAE is generally discussed as an option for patients with mild-to-moderate knee osteoarthritis whose pain persists despite conservative treatments such as physical therapy, weight management, and medication, and who are not yet ready for — or are not candidates for — total knee replacement. It is not positioned as a replacement for joint replacement surgery in patients with advanced structural joint damage. A qualified physician determines candidacy based on imaging findings, symptom severity, and overall treatment goals.
What Does Recovery Typically Involve?
Recovery from genicular artery embolization is generally described as brief compared with surgical knee procedures, with most patients returning home the same day and resuming light activity within a short period. Some patients report mild soreness or skin discoloration near the knee in the days following the procedure, which is commonly self-limiting. As with other embolization procedures, symptom improvement is often gradual rather than immediate.
Embolic Devices Used in Genicular Procedures
Genicular artery embolization requires embolic agents capable of precise, small-vessel delivery through microcatheters navigating tortuous distal branches around the knee. INVAMED develops embolization technologies used across interventional radiology applications; further details are available on the INVAMED embolization products page. Availability and indications vary by country, and the Instructions for Use (IFU) should always be consulted by treating clinicians.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.